Evidence map›Paper›PMID 38927403›Full record

ArticleBiomedicines2024

Molecular and Evolution

Alfonso Trezza, Ancuta Birgauan, Michela Geminiani, Anna Visibelli, Annalisa Santucci

Abstract read
In one paragraph

Article in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Marine drugs · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Alfonso TrezzaDepartment of Biotechnology, Chemistry, and Pharmacy, University of Siena, Via Aldo Moro, 53100 Siena, SI, Italy.
Ancuta BirgauanDepartment of Biotechnology, Chemistry, and Pharmacy, University of Siena, Via Aldo Moro, 53100 Siena, SI, Italy.
Michela GeminianiDepartment of Biotechnology, Chemistry, and Pharmacy, University of Siena, Via Aldo Moro, 53100 Siena, SI, Italy.ORCID 0000-0002-6910-0056
Anna VisibelliDepartment of Biotechnology, Chemistry, and Pharmacy, University of Siena, Via Aldo Moro, 53100 Siena, SI, Italy.ORCID 0000-0001-9281-034X
Annalisa SantucciDepartment of Biotechnology, Chemistry, and Pharmacy, University of Siena, Via Aldo Moro, 53100 Siena, SI, Italy.ORCID 0000-0001-6976-9086

Funding

PNRR-PRIN2022 2265-2023-SA-PROFCMUR_PNRR-PRIN2022_PC_002
6 · The paper itself

Abstract

The enzyme 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) is involved in the catabolism of the amino acid tyrosine in organisms such as bacteria, plants, and animals. It catalyzes the conversion of 4-hydroxyphenylpyruvate to a homogenisate in the presence of molecular oxygen and Fe(II) as a cofactor. This enzyme represents a key step in the biosynthesis of important compounds, and its activity deficiency leads to severe, rare autosomal recessive disorders, like tyrosinemia type III and hawkinsinuria, for which no cure is currently available. The 4-HPPD C-terminal tail plays a crucial role in the enzyme catalysis/gating mechanism, ensuring the integrity of the active site for catalysis through fine regulation of the C-terminal tail conformation. However, despite growing interest in the 4-HPPD catalytic mechanism and structure, the gating mechanism remains unclear. Furthermore, the absence of the whole 3D structure makes the bioinformatic approach the only possible study to define the enzyme structure/molecular mechanism. Here, wild-type 4-HPPD and its mutants were deeply dissected by applying a comprehensive bioinformatics/evolution study, and we showed for the first time the entire molecular mechanism and regulation of the enzyme gating process, proposing the full-length 3D structure of human 4-HPPD and two novel key residues involved in the 4-HPPD C-terminal tail conformational change.

Indexed as

4-HPPDC-terminal tailgatingmolecular dynamics simulationsmolecular modelingmultiple sequence alignmentmutagenesisprotein evolution

Identifiers

PMID38927403
PMCPMC11201076

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.